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Abstract
We aim to explore real-world biological survival stratified for discontinuation reason and determine its influenceability in rheuma-
toid arthritis (RA) patients. Data from the local pharmacy database and patient records of a university hospital in the Netherlands
were used. RA patients who started a biological between 2000 and 2020 were included. Data on age, anti-citrullinated protein
antibody (ACPA) and rheumatoid factor (RF) status, presence of erosions, gender, body mass index, time to first biological,
biological survival time, use of csDMARDs, and discontinuation reasons were collected. Of the included 318 patients, 12% started
their first biological within 6 months after diagnosis. The median time to first biological was 3.6 years (95% CI, 1.0–7.2). The
median survival of the first- and second-line biological was respectively 1.7 years (95%CI, 1.3–2.2) and 0.8 years (95%CI, 0.5–1.0)
(p = 0.0001). Discontinuation reasons for the first-line biological were ineffectiveness (47%), adverse events (17%), remission
(16%), pregnancy (30%), or patient preference (10%).Multivariable Cox regression analyses for discontinuation due to inefficacy or
adverse events showed that concomitant use of csDMARDs (HR = 1.32, p < 0.001) positively while RF positivity negatively (HR =
0.82, p = 0.03) influenced biological survival. ACPA positivity was associated with the inability to discontinue biologicals after
achieving remission (HR = 1.43, p = 0.023). Second-line TNF inhibitor survival was similar between patients with a primary and
secondary non-response on the first-line TNF inhibitor (HR = 1.28, p = 0.34). Biological survival diminishes with the number of
biologicals used. Biological survival is prolonged if patients use csDMARDs. RF was negatively associated with biological
survival. ACPA was negatively associated with the inability to discontinue biologicals after achieving remission. Therefore,
tailoring treatment based upon autoantibody status might be the first step towards personalized medicine in RA.
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Introduction
Management of RA has improved in the last decades due to
early diagnosis, a treat-to-target approach, and the introduc-
tion of biological disease-modifying anti-rheumatic drugs
(bDMARDs) [1]. Tumor necrosis factor inhibitors (TNF in-
hibitors) were the first bDMARDs to be developed for rheu-
matic diseases and are currently most frequently prescribed
after an inadequate response to conventional synthetic
(cs)DMARDs. It has been suggested that prolonged biological
Key Points
• Prolonged biological survival is a surrogate for treatment effectiveness; however, an increasing amount of patients will taper treatment due to
remission, and factors influencing biological survival based on separate reasons for discontinuation have not been explored.
• We found that combining a biological DMARD with a conventional synthetic DMARD increases biological DMARD survival. Rheumatoid factor is
negatively associated with biological survival. Anti-citrullinated protein antibody is negatively associated with the inability to discontinue the
biological when remission was reached.
• The first step towards personalized medicine might be tailoring of treatment based upon autoantibody status.
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survival is a surrogate for treatment effectiveness [2]. Since
more patients reach remission nowadays, more patients will
be able to taper and discontinue treatment [1]. Therefore, sole-
ly taking into account overall biological survival will dilute
outcomes, and to properly analyze biological survival, results
should be stratified according to discontinuation reasons.
Previous studies, based on biological registries throughout
Europe, have shown that 50% of patients discontinue their
TNF inhibitor within 3–5 years [3]. Main reasons for discon-
tinuation were inefficacy and adverse events [3, 4]. Within
trials and biological registries, longer survival times were seen
for first-line biologicals and when bDMARDS were com-
bined with csDMARDs [5–7]. However, factors influencing
biological survival based on separate reasons for discontinua-
tion have not been previously explored.
Therefore, the aim of this Dutch real-world rheumatoid
arthritis cohort is to explore first- and second-line biological




Data from a retrospective cohort were used, which we derived
from the local pharmacy database and patient records of the
Erasmus MC, an academic hospital in the Netherlands. We
included data from rheumatoid arthritis (RA) patients starting
a biological between 2000 and 2020.We excluded patients for
whom non-adherence was reported, and if start and stop dates
for bDMARDs were not available. Standard treatment of RA
in the Netherlands is based upon a treat-to-target approach
aiming for low disease activity. Methotrexate, unless contra-
indicated, is the first choice of treatment after being diagnosed
with RA. If the treatment target is not reached, another con-
ventional synthetic (cs)DMARD can be started. If patients
have an inadequate response to > 1 csDMARD, a bDMARD
can be prescribed. In case of an inadequate response, rheuma-
tologists can prescribe another bDMARDwith the samemode
of action (cycling) or a bDMARD with another mode of ac-
tion (switching) [8].
Data collection
Biological survival was the main outcome. Discontinuation
was defined as skipping ≥ 2 doses and/or ≥ 2 months without
biological treatment. Reasons for discontinuations were eval-
uated and classified into inefficacy, which we divided into
primary (< 6 months) and secondary (≥ 6 months) non-
response; adverse events (AEs); remission; pregnancy; patient
preference; and other reasons.
Analyses
We compared first- and second-line biological survival with
Kaplan-Meier curves and with Wilcoxon-Breslow-Gehan
tests at 3 years. Thereafter, first-line biological survival with
and without concomitant use of csDMARD(s) was compared.
Subsequently, we investigated whether primary and second-
ary inefficacy to a first-line TNF inhibitor leads to differences
in second-line TNF inhibitor survival. Patients stopping their
bDMARD due to remission or pregnancy were censored.
Cox proportional hazard models were used to estimate haz-
ard ratios (HRs) of candidate baseline predictors (age, gender,
ACPA, RF, erosions, BMI, DAS28, disease duration, or co-
medication) for bDMARD survival stratified for reasons for
discontinuation, namely (1) inefficacy or adverse events and
(2) remission. First univariable Cox regression analyses were
performed, and candidate predictors with a p < 0.20 were en-
tered into a multivariable model, after which backward selec-
tion was applied until significance was reached. To prevent
overfitting, an entry model was created and backward selec-
tion was applied. Schoenfeld residuals were assessed to check
the proportional hazard assumption.
All data was analyzed using STATA 15. p values ≤ 0.05
were considered statistically significant.
Results
Patients
Data were derived from 318 RA patients (Table 1). Time until
first bDMARD prescription remained constant between 2000
and 2020. In our cohort, 50% of patients started their first
biological after 2013; thus, in most recent years, more
bDMARDs were prescribed. A total of 39 (12%) patients
started their first bDMARD within 6 months after diagnosis.
First- and second-line biological survival
The median (95% CI) survival time of the first-line biological
was 1.7 years (1.3–2.2), and for the second-line bDMARD,
0.8 years (0.5–1). Themost prescribed first-line bDMARDswere
etanercept (45%), adalimumab (28%), and certolizumab pegol
(19%) (Table 1). Since only 9% of patients were using non-
TNF inhibitors as second-line bDMARD, a direct comparison
between a cycling and switching strategy could not be performed.
bDMARD survival was significantly longer for the first-
line bDMARD compared to the second (p = 0.0001) (Fig. 1a).
Discontinuation reasons for the first-line bDMARD were in-
efficacy (47%), adverse events (17%), remission (16%), preg-
nancy (30%), or patient preference (10%). Discontinuation
reasons for the second-line bDMARD were similar
(supplemental table S1).
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First-line biological survival with or without
concomitant use of csDMARDs
A total of 48 (25.3%) and 6 (15.4%) patients respectively with
and without concomitant use of csDMARD(s) were still using
their first-line biological after 3 years of follow-up. The me-
dian (95% CI) survival time of the first-line bDMARD with
csDMARD(s) was 2.0 (1.3–2.3) years, and without
csDMARDs, 1.0 (0.5–5.3) year (Fig. 1b, p = 0.031). First-
line bDMARD survival was longest for treatment regimens
with methotrexate (MTX) followed by other csDMARDs, and
no csDMARD use (Fig. 1c). However, no significant differ-
ences were found between MTX and the other csDMARDs as
concomitant therapy (p = 0.14) (Fig. 1c).
Primary and secondary failure
The median (95% CI) survival time for the second-line TNF
inhibitor was 0.42 (0.25–1.58) years for patients with a
primary non-response for the first TNF inhibitor and 0.92
(0.83–1.83) years for patients with a secondary non-response
for the first TNF inhibitor. Although overall survival time on
the second-line biological did not differ significantly between
patients with a primary and secondary non-response (HR
1.28, p = 0.34), a trend could be observed (Fig. 1d).
Predictors for biological survival
Univariate Cox regression for discontinuation due to inefficacy
and adverse events showed that RF (HR = 0.80, p = 0.014) and
presence of erosions (HR = 0.65, p < 0.001) were negatively
associated with bDMARD survival. Concomitant use of
csDMARD(s) (HR = 1.35, p < 0.001) on the other hand was
positively associated with bDMARD survival. The aforemen-
tioned factors as well as time to bDMARD, age, gender, and
ACPA were included in our multivariable model with back-
ward selection. In the final model, only RF (HR = 0.82, p =
0.03) and concomitant use of csDMARDs (HR = 1.32, p =
0.001) were significantly associated with bDMARD survival
(Table 2).When we used an entry model and applied backward
selection, the aforementioned predictors were again in the final
model, but also the presence of erosions was included.
The same procedure was followed for investigating which
factors were associated with a higher chance of discontinuing
bDMARDs due to remission. Only a positive ACPA status
was associated with longer biological survival due to inability
to taper medication (HR = 1.43, p = 0.023) (Table 2).
Discussion
Optimal management of RA is based on reaching the lowest
possible disease activity with a treat-to-target approach [1].
Despite the improved management approach and increasing
treatment options, only 60–70% of RA patients will reach a
long-term clinical response [4]. Within our study, we found a
significant difference in survival time between the first- and
second-line bDMARD, implicating the importance to prolong
first-line bDMARD survival. Several factors can influence
bDMARD survival of which some can be influenced.
Main reasons for discontinuation in our and in other studies
were inefficacy and adverse events [3]. Primary inefficacy
indicates no effect at all, and is thought to be due to a mis-
match between the bDMARD and the specific RA subtype,
causing the biologic agent not to be effective [9]. Secondary
inefficacy indicates that the clinical response is first obtained,
but not maintained, and is thought to be caused by formation
of autoantibodies against the biologic [4]. Although we did
not find a significant difference in second-line TNF inhibitor
survival between RA patients with a primary or secondary
non-response to the first TNF inhibitor, a trend could be ob-
served. This was probably due to a low number of patients in
Table 1 Characteristics of rheumatoid arthritis population using a




• Age at diagnosis, mean (SD) 40.9 (16)
• Gender, female, n (%) 264 (83)
• BMI, mean (SD) 26.9 (6.3)
Disease characteristics
• ACPA positive, n (%) 224 (70)
• RF positive, n (%) 226 (71)
• Erosive disease, n (%) 141 (44)
Medication
• Time to first biological (years), median (IQR) 3.6 (1–7)
• First-line biologicals
○ Etanercept, n (%) 142 (45)
○ Adalimumab, n (%) 90 (28)
○ Certolizumab pegol, n (%) 59 (19)
○ Infliximab, n (%) 15 (5)
○ Golimumab, n (%) 5 (2)
○ Anakinra, n (%) 3 (1)
• csDMARDs used with first-line biological
○ MTX, n (%) 66 (21)
○ MTX + SASP and/or HCQ, n (%) 147 (46)
○ Other csDMARDs (SASP, HCQ, LEF), n (%) 53 (17)
○ No combination therapy, n (%) 52 (16)
ACPA anti-citrullinated protein antibody, BMI body mass index,
csDMARD conventional synthetic disease-modifying anti-rheumatic
drug, HCQ hydroxychloroquine, IQR interquartile range, LEF
leflunomide, MTX methotrexate, RF rheumatoid factor, SASP
sulfasalazine, SD standard deviation
Clin Rheumatol
the group with a primary non-response for the first-line
bDMARD (n = 42). However, these data indicate that rheu-
matologists should consider switching to another mode of
action in case of primary inefficacy instead of cycling to an-
other TNF inhibitor, but validation is needed [10, 11].
Compared to previous findings, bDMARD survival seems
to be short. This can be explained by the setting of our cohort
in a tertiary care university hospital, which usually includes
more difficult to treat and/or refractory RA patients.
Furthermore, within an academic environment, patients are
often participating in (treatment) trials, which could influence
the results. For instance, the treatment in the Rotterdam Early
Arthritis Cohort (tREACH) trial and the tapering strategies in
RA (TARA) trial were initiated in the Erasmus MC [12, 13].
Furthermore, the Erasmus MC participated in the POET trial,
which was also a tapering trial [14]. However, these trials
were all following a treat-to-target strategy, which probably
did not influence our results much. Besides these trials, a large
proportion of the patients discontinued their bDMARD due to
pregnancy. This is related to the fact that Erasmus MC has an
ongoing cohort for patients with a wish to conceive [15].
Consequently, a high number of patients were using
certolizumab pegol, which is known to be safe to use during
pregnancy.
Outcomes of our study on the other hand are in accordance
with previous findings. Benefits of combining a bDMARD
with a csDMARD have been previously described [6, 16,
17]. Reasons for this synergistic effect are not fully under-
stood. Soliman et al. investigated the csDMARDs separately
and found the strongest effect on prolongation of biological
survival when MTX was combined [16]. Unfortunately, we
lacked power to confirm this for subgroups within the
csDMARDs in our study. One of the reasons could be that
csDMARDs can prevent development of neutralizing anti-
drug antibodies. It is also thought that csDMARDs affect
clearance of the bDMARD by modulating either the expres-
sion of Fc receptors on monocytes or the interaction of the Fc
receptor and the bDMARD [4].
Another factor that could influence biological survival is
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Fig. 1 Kaplan-Meier curves for biological survival. a Kaplan-Meier for
first- versus second-line biological survival. b Kaplan-Meier curve of
patients with or without combination therapy. c Kaplan-Meier curve of
patients without combination therapy, and for patients with combination
therapy stratified for methotrexate, methotrexate combined with one or
more other csDMARDs (sulfasalazine, hydroxychloroquine, and/or
leflunomide), or one or more other csDMARDs. d Kaplan-Meier of
second-line TNF inhibitor survival, stratified for primary and secondary
inefficacy for the first-line TNF inhibitor. csDMARD, conventional syn-
thetic disease-modifying anti-rheumatic drug; MTX, methotrexate
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and uses a certain drug, the lower the adherence [18].
Furthermore, patients’ beliefs on the efficacy of the
drug could play a role [19, 20]. For example, we al-
ready showed that biological survival improves if com-
bined with a csDMARDs. And if patients believe that
the csDMARDs are necessary, their compliance will in-
crease, which will probably result in an even better
biological survival.
Previous literature already showed that the presence of au-
toantibodies in RA is associated with a worse treatment re-
sponse and outcome. Moreover, autoantibody-negative RA
patients have a better treatment response compared to
autoantibody-positive RA patients when given similar thera-
pies [21]. In accordance with previous literature, we found a
shortened biological survival due to inefficacy or adverse
events in RF-positive RA patients but also the inability to
taper TNF inhibitors after reaching remission in ACPA-
positive RA patients [22]. This reconfirms the fact that auto-
antibody positivity is associated with worse outcomes and
indicates that RA can be subdivided into autoantibody-
positive and autoantibody-negative RA. This also suggests
that treatment maybe stratified on autoantibody status, but
validation is needed.
In conclusion, bDMARD survival diminishes with the
number of bDMARDs used. Combining a bDMARD with a
csDMARD increases bDMARD survival, which supports cur-
rent EULAR recommendations to combine a bDMARD with
a csDMARD. RF and ACPA were negatively associated with
respectively bDMARD survival and discontinuation due to
remission. Therefore, the possible first step to personalized
medicine in RA might be tailoring of treatment based upon
autoantibody status.
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Table 2 Predictors for overall
biological survival Univariable Multivariable
1
HR (95% CI) p HR (95% CI) p
Biological survival taking into account discontinuation due to inefficacy or AEs2
Age at diagnosis 1.00 (1.00–1.01) 0.514
Gender (female) 1.00 (0.82–1.23) 0.985
BMI 0.99 (0.98–1.01) 0.296
Rheumatoid factor 0.80 (0.67–0.96) 0.014 0.82 (0.69–0.98) 0.03
ACPA 0.90 (0.75–1.07) 0.223
Erosions 0.65 (0.55–0.76) <0.001
Time to first-line biological 0.98 (0.95–1.01) 0.163
Combination therapy 1.35 (1.14–1.59) <0.001 1.32 (1.13–1.57) 0.001
DAS28 at time of discontinuation 1.02 (0.87–1.21) 0.754
Prolonged biological survival due to inability to taper3
Age at diagnosis 1.00 (0.99–1.01) 0.717
Gender (female) 1.08 (0.75–1.56) 0.676
BMI 0.98 (0.95–1.01) 0.175
Rheumatoid factor 1.26 (0.94–1.96) 0.121
ACPA 1.43 (1.05–1.93) 0.023 1.43 (1.05–1.93) 0.023
Erosions 0.70 (0.53–0.92) 0.481
Time to first-line biological 1.04 (0.99–1.09) 0.119
Combination therapy 0.93 (0.69–1.26) 0.643
DAS28 at time of discontinuation 0.81 (0.49–1.36) 0.430
1 Backward selection, variables with p < 0.20 in univariable analyses were entered. 2HR > 1 indicates prolonged
biological survival; HR < 1 indicates reduced biological survival due to inefficacy or AEs. 3 HR > 1 indicates
prolonged biological survival due to inability to taper; HR < 1 indicates reduced biological survival due to
tapering of bDMARD due to remission. Bold numbers within the univariable column indicate HRs which had
a p < 0.2, bold numbers within the multivariable column indicate HRs with a p < 0.05
ACPA anti-citrullinated protein antibody, AEs adverse events, BMI bodymass index,CI confidence interval,DAS
Disease Activity Score, HR hazard ratio
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